Literature DB >> 12230274

Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG.

E Pieras-Ayala1, J Palou-Redorta, J I Tomero-Ruiz, M Montlleó-González, J Salvador-Bayarri, J Vicente-Rodríguez.   

Abstract

OBJECTIVE: The aim of this study is to find out whether the pseudotumoral lesions (inflammation/granuloma) seen at the follow-up cystoscopy performed three to six months after transurethral resection of primary stage T1 grade 3 bladder tumor and instillations of BCG therapy might have some prognostic value as far as recurrence and/or long term progression are concerned.
MATERIAL AND METHODS: From the first group of one hundred and thirteen patients with primary stage of T1 grade 3 bladder tumor treated with 81 mg of BCG Connaught (weekly/during six weeks), those with recurrent tumor at the 3rd and 6th month were excluded, so we evaluated 99 patients. We identified 13 patients with cystoscopically pseudotumoral lesions.
RESULTS: of the 13 cystoscopically pseudotumoral lesions, we observed recurrence in two cases (15%), while among the rest of the 86 patients, we observed 22 recurrences (26%) (p = 0.9; not significant). Concerning progression, eight cases were reported out of 86 patients (9%) within the cistocopically normal group. No cases of progression were reported among the 13 patients with cystoscopically pseudotumoral lesions. This difference was not statistically significant (p = 0.5).
CONCLUSIONS: The patients with cystoscopically pseudotumoral lesions (inflammation/granuloma) are a reduced group (13%) with less tendency to recurrence and without progression, even though this relationship is not significant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12230274     DOI: 10.1023/a:1019533806868

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

Review 1.  Preventing progression and improving survival with BCG maintenance.

Authors:  D L Lamm
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

2.  [Cytoscopic follow-up of initial G3T1 bladder tumors treated with BCG].

Authors:  E Pieras Ayala; J Palou; L Rodríguez-Villamil; F Millán Rodríguez; J Salvador Bayarri; J Vicente Rodríguez
Journal:  Arch Esp Urol       Date:  2001-04       Impact factor: 0.436

3.  Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.

Authors:  J A Martínez-Piñeiro; J Jiménez León; L Martínez-Piñeiro; L Fiter; J A Mosteiro; J Navarro; M J García Matres; P Cárcamo
Journal:  J Urol       Date:  1990-03       Impact factor: 7.450

4.  Local immune responses after intravesical BCG treatment for carcinoma in situ.

Authors:  M I el-Demiry; G Smith; A W Ritchie; K James; J A Cumming; T B Hargreave; G D Chisholm
Journal:  Br J Urol       Date:  1987-12

5.  Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?

Authors:  J S Teppema; E C de Boer; P A Steerenberg; A P van der Meijden
Journal:  Urol Res       Date:  1992

6.  Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.

Authors:  R Hurle; A Losa; A Ranieri; P Graziotti; A Lembo
Journal:  J Urol       Date:  1996-11       Impact factor: 7.450

Review 7.  Multivariate analysis of the prognostic factors of primary superficial bladder cancer.

Authors:  F Millán-Rodríguez; G Chéchile-Toniolo; J Salvador-Bayarri; J Palou; J Vicente-Rodríguez
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.

Authors:  P F Schellhammer; L E Ladaga; M B Fillion
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

9.  Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.

Authors:  D R Kelley; E O Haaff; M Becich; J Lage; W C Bauer; S M Dresner; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

10.  Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.

Authors:  T M de Reijke; E C de Boer; K H Kurth; D H Schamhart
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

View more
  2 in total

1.  Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy.

Authors:  Masashi Matsushima; Eiji Kikuchi; Hirotaka Akita; Akira Miyajima; Mototsugu Oya; Masahiro Jinzaki
Journal:  Int J Clin Oncol       Date:  2017-02-10       Impact factor: 3.402

Review 2.  Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.

Authors:  Jelmer H van Puffelen; Samuel T Keating; Egbert Oosterwijk; Antoine G van der Heijden; Mihai G Netea; Leo A B Joosten; Sita H Vermeulen
Journal:  Nat Rev Urol       Date:  2020-07-16       Impact factor: 14.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.